Literature DB >> 24462293

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Vanessa Almendro1, Yu-Kang Cheng2, Amanda Randles3, Shalev Itzkovitz4, Andriy Marusyk5, Elisabet Ametller6, Xavier Gonzalez-Farre6, Montse Muñoz6, Hege G Russnes7, Aslaug Helland8, Inga H Rye9, Anne-Lise Borresen-Dale9, Reo Maruyama5, Alexander van Oudenaarden10, Mitchell Dowsett11, Robin L Jones12, Jorge Reis-Filho13, Pere Gascon6, Mithat Gönen14, Franziska Michor15, Kornelia Polyak16.   

Abstract

Cancer therapy exerts a strong selection pressure that shapes tumor evolution, yet our knowledge of how tumors change during treatment is limited. Here, we report the analysis of cellular heterogeneity for genetic and phenotypic features and their spatial distribution in breast tumors pre- and post-neoadjuvant chemotherapy. We found that intratumor genetic diversity was tumor-subtype specific, and it did not change during treatment in tumors with partial or no response. However, lower pretreatment genetic diversity was significantly associated with pathologic complete response. In contrast, phenotypic diversity was different between pre- and posttreatment samples. We also observed significant changes in the spatial distribution of cells with distinct genetic and phenotypic features. We used these experimental data to develop a stochastic computational model to infer tumor growth patterns and evolutionary dynamics. Our results highlight the importance of integrated analysis of genotypes and phenotypes of single cells in intact tissues to predict tumor evolution.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24462293      PMCID: PMC3928845          DOI: 10.1016/j.celrep.2013.12.041

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  49 in total

1.  Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers.

Authors:  P Collecchi; E Baldini; P Giannessi; A G Naccarato; A Passoni; G Gardin; M Roncella; G Evangelista; G Bevilacqua; P F Conte
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

2.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

3.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

Authors:  Carlo C Maley; Patricia C Galipeau; Jennifer C Finley; V Jon Wongsurawat; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Patricia L Blount; Rosa-Ana Risques; Peter S Rabinovitch; Brian J Reid
Journal:  Nat Genet       Date:  2006-03-26       Impact factor: 38.330

4.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

Review 7.  Tumor heterogeneity and the biology of cancer invasion and metastasis.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

8.  The cell kinetics of human mammary cancers.

Authors:  L M Schiffer; P G Braunschweiger; J J Stragand; L Poulakos
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

9.  High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma.

Authors:  Edmund A Mroz; Aaron D Tward; Curtis R Pickering; Jeffrey N Myers; Robert L Ferris; James W Rocco
Journal:  Cancer       Date:  2013-05-20       Impact factor: 6.860

10.  Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.

Authors:  So Yeon Park; Mithat Gönen; Hee Jung Kim; Franziska Michor; Kornelia Polyak
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

View more
  132 in total

Review 1.  How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity.

Authors:  Padmashree C G Rida; Guilherme Cantuaria; Michelle D Reid; Omer Kucuk; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

2.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 3.  The evolution of tumour phylogenetics: principles and practice.

Authors:  Russell Schwartz; Alejandro A Schäffer
Journal:  Nat Rev Genet       Date:  2017-02-13       Impact factor: 53.242

4.  Tumor evolution in response to chemotherapy: phenotype versus genotype.

Authors:  Nicholas E Navin
Journal:  Cell Rep       Date:  2014-02-13       Impact factor: 9.423

5.  Frameshift Mutations in the Mononucleotide Repeats of TAF1 and TAF1L Genes in Gastric and Colorectal Cancers with Regional Heterogeneity.

Authors:  Hye Rim Oh; Chang Hyeok An; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-08-29       Impact factor: 3.201

6.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.

Authors:  Roman Reinartz; Shanshan Wang; Sied Kebir; Daniel J Silver; Anja Wieland; Tong Zheng; Marius Küpper; Laurèl Rauschenbach; Rolf Fimmers; Timothy M Shepherd; Daniel Trageser; Andreas Till; Niklas Schäfer; Martin Glas; Axel M Hillmer; Sven Cichon; Amy A Smith; Torsten Pietsch; Ying Liu; Brent A Reynolds; Anthony Yachnis; David W Pincus; Matthias Simon; Oliver Brüstle; Dennis A Steindler; Björn Scheffler
Journal:  Clin Cancer Res       Date:  2016-08-12       Impact factor: 12.531

7.  Single-Cell RNA Sequencing of Ovarian Cancer: Promises and Challenges.

Authors:  Shobhana Talukdar; Zenas Chang; Boris Winterhoff; Timothy K Starr
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  JARID1B is a luminal lineage-driving oncogene in breast cancer.

Authors:  Shoji Yamamoto; Zhenhua Wu; Hege G Russnes; Shinji Takagi; Guillermo Peluffo; Charles Vaske; Xi Zhao; Hans Kristian Moen Vollan; Reo Maruyama; Muhammad B Ekram; Hanfei Sun; Jee Hyun Kim; Kristopher Carver; Mattia Zucca; Jianxing Feng; Vanessa Almendro; Marina Bessarabova; Oscar M Rueda; Yuri Nikolsky; Carlos Caldas; X Shirley Liu; Kornelia Polyak
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

Review 9.  The dynamic control of signal transduction networks in cancer cells.

Authors:  Walter Kolch; Melinda Halasz; Marina Granovskaya; Boris N Kholodenko
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

10.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity.

Authors:  Noemi Andor; Trevor A Graham; Marnix Jansen; Li C Xia; C Athena Aktipis; Claudia Petritsch; Hanlee P Ji; Carlo C Maley
Journal:  Nat Med       Date:  2015-11-30       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.